- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01188512
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine
A Phase 1, Single Centre, Dose-escalating, Placebo-controlled Study of a Genetically Modified B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Male Volunteers
The purpose of this study is to evaluate the safety and immunogenicity of a new live attenuated vaccine against whooping-cough. It is a phase1, single centre, dose-escalating, placebo-controlled study on a genetically modified B. pertussis strain given as a single intranasal dose to healthy adult male volunteers.
Effective vaccines are needed to protect young infants (from 0 to 6 months, today the most vulnerable age group), preferably after a single administration very early in life. The successful outcome of this project would constitute an important milestone towards nasal vaccination of infants, possibly at birth with a novel, single-dose pertussis vaccine. Our ultimate aim is to protect infants in the most vulnerable age group, before the regular vaccination schedule using already available vaccines is applied. The ultimate aim is thus not to replace current vaccination schedules with available vaccines, but to add a first nasal vaccination to protect very early in life.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Solna, Suecia, 171 76
- Karolinska University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Subject will be included in the study if he meets all the following criteria:
- Healthy male born between 1979 and 1991 who has not experienced clinical pertussis (lab. Verified) during the past 10 years and who has not been vaccinated with any pertussis vaccine.
- Informed consent form signed by the subject.
- Subject shall be able to attend all scheduled visits and to understand and comply with the study procedures (e.g. able to read and write Swedish).
Exclusion Criteria:
If any of the following criteria are met, the subject must not be included in the study:
- Individuals with pertussis toxin serum IgG antibodies ≥20 units/mL.
- Blood pressure after resting ≥ 150/90 mmHg.
- Heart rate after resting ≥80 bpm.
- Respiratory rate after resting ≥ 20/minute.
- Unwillingness to refrain from the use of nicotine products from screening through day 28.
- Use of narcotic drugs/alcohol and/or a history of previous use of drug/alcohol abuse whitin the past 2 years prior to screening
- The subject has donated blood or suffered from blood loss of at least 450 ml (1 unit of blood) within 60 days prior to screening or donated plasma within 14 days prior to screening.
- Receipt of immunoglobulin, blood derived products, systemic corticosteroids or other immunosuppressant drugs within 90 days prior to day 0.
- Use of corticosteroids in the respiratory tract(e.g. nasal steroids, inhaled steroids) whitin 30 days prior to day 0.
- Use of herbal medications or dietary supplements within 7 days prior to day 0 at the discretion of the investigator. Unwillingness to refrain from herbal medications or dietary supplements within 30 days after day 0 at the discretion of the investigator.
- Receipt of a vaccine within the last 30 days prior to day 0 or planned vaccination within the next 30 days after day 0.
- Evolving encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of any vaccine.
- Known hypersensitivity to any component of the study vaccine.
- Current participation in any other clinical trial or participation (and during the whole study) in any clinical trial in the previous 3 months prior to day 0.
- Inability to adhere to the protocol, including plans to move from the area.
- Family history of congenital or hereditary immunodeficiency (first degree).
- Infection with HIV, hepatitis B or C.
- Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
- Clinically significant abnormal laboratory values at the discretion of the investigator.
- Person in frequent contact with children less than 1 year of age (father, childcare worker, nurse, etc…) or residence in the same household as persons with known immunodeficiency.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador de placebos: Placebo
Tampón de formulación
|
Individuals will get placebo once intranasally.
Dose 2 x 0.1 mL (0.1 mL per nostril).
|
Experimental: BPZE1 - Low dose
1,000 colony forming units (cfu) of BPZE1
|
Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
|
Experimental: BPZE1- middle dose
100,000 colony forming units (cfu) of BPZE1
|
Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
|
Experimental: BPZE1 - High dose
10,000,000 colony forming units (cfu) of BPZE1
|
Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
General safety and local tolerability in the respiratory tract of a single ascending dose of the genetically modified B. pertussis strain
Periodo de tiempo: 6 months
|
To determine
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Attachment of the BPZE1 strain to the nasopharyngeal mucosa
Periodo de tiempo: Up to 50 days after vaccination
|
Detection of colonizing BPZE1 bacteria in nasopharyngeal culture
|
Up to 50 days after vaccination
|
Immunogenicity
Periodo de tiempo: 6 months
|
Immune responses will be determined by serum IgG and IgA, IgG and IgA in saliva and nasopharyngeal aspirate, cytokines and numbers of effector and memory T and B cells after stimulation with the various B. pertussis antigens.
|
6 months
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Nabil Al-Tawil, MD, PhD, Karolinska Trial Alliance
- Director de estudio: Camille Locht, PhD, Institut National de la Santé Et de la Recherche Médicale, France
- Investigador principal: Rigmor Thorstensson, PhD, Swedish Institute for Infectious Disease Control
Publicaciones y enlaces útiles
Publicaciones Generales
- Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008 Oct 23;26(45):5722-7. doi: 10.1016/j.vaccine.2008.08.018. Epub 2008 Aug 30.
- Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, Creusy C, Engle J, Goldman WE, Locht C. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2006 Jul;2(7):e65. doi: 10.1371/journal.ppat.0020065.
- Mielcarek N, Debrie AS, Mahieux S, Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol. 2010 Mar;17(3):317-24. doi: 10.1128/CVI.00322-09. Epub 2010 Jan 27.
- Skerry CM, Cassidy JP, English K, Feunou-Feunou P, Locht C, Mahon BP. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol. 2009 Sep;16(9):1344-51. doi: 10.1128/CVI.00082-09. Epub 2009 Jul 22.
- Kavanagh H, Noone C, Cahill E, English K, Locht C, Mahon BP. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy. 2010 Jun;40(6):933-41. doi: 10.1111/j.1365-2222.2010.03459.x. Epub 2010 Feb 22.
- Jahnmatz M, Amu S, Ljungman M, Wehlin L, Chiodi F, Mielcarek N, Locht C, Thorstensson R. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial. Vaccine. 2014 Jun 5;32(27):3350-6. doi: 10.1016/j.vaccine.2014.04.048. Epub 2014 Apr 29.
- Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergstrom J, Ljungman M, Torner A, Wehlin L, Van Broekhoven A, Bosman F, Debrie AS, Mielcarek N, Locht C. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014 Jan 8;9(1):e83449. doi: 10.1371/journal.pone.0083449. eCollection 2014.
- Schnoeller C, Roux X, Sawant D, Raze D, Olszewska W, Locht C, Openshaw PJ. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Crit Care Med. 2014 Jan 15;189(2):194-202. doi: 10.1164/rccm.201307-1227OC.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- BT06-04
- 2010-019936-11 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Tos ferina
-
University of VirginiaDesconocidoTransporte de Bordetella PertussisEstados Unidos
-
Institut PasteurHopital Universitaire Robert-Debre; Hospices Civils de Lyon; Centre Hospitalier... y otros colaboradoresAún no reclutandoBordetella pertussis, tos ferinaFrancia
-
ILiAD BiotechnologiesActivo, no reclutandoBordetella pertussis, tos ferinaReino Unido, Australia, Costa Rica
-
University of TurkuGlaxoSmithKline; Sanofi Pasteur, a Sanofi CompanyTerminadoBordetella pertussis, tos ferinaFinlandia
-
Institut PasteurAgence de Médecine Préventive, France; Institut Pasteur de Madagascar; Institut...TerminadoBordetella pertussis, tos ferinaCamboya, Madagascar, Para llevar
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireTerminadoBordetella pertussis, tos ferinaCosta de Marfil
-
University Hospital, GhentGlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; Novartis Vaccines; University... y otros colaboradoresTerminadoPrevención de Infecciones por Bordetella PertussisBélgica
-
Luminex Molecular DiagnosticsTerminadoInfecciones por Bordetella | Infección por Bordetella Pertussis | Infección por Bordetella ParapertussisEstados Unidos, Canadá
-
ILiAD BiotechnologiesTerminadoTos ferina/tos ferina | Bordetella pertussis, tos ferinaReino Unido
-
GlaxoSmithKlineTerminadoHepatitis A | Citomegalovirus | Infección por Bordetella Pertussis | Vacunas contra la hepatitis viral | Virus de la varicela zoster | Herpes simple (1 y 2)México
Ensayos clínicos sobre BPZE1
-
National Institute of Allergy and Infectious Diseases...TerminadoTos ferina | Inmunización contra la tos ferinaEstados Unidos
-
Institut National de la Santé Et de la Recherche...TerminadoTos ferina | Tos ferinaSuecia
-
ILiAD BiotechnologiesActivo, no reclutandoBordetella pertussis, tos ferinaReino Unido, Australia, Costa Rica
-
ILiAD BiotechnologiesPPDTerminadoTos ferina | Tos ferinaEstados Unidos
-
ILiAD BiotechnologiesTerminadoTos ferina/tos ferina | Bordetella pertussis, tos ferinaReino Unido